MOUNTAIN Look at, Calif. & SOUTH SAN FRANCISCO, Calif.–(Organization WIRE)–DNAnexus, Inc., a primary company of cloud-based biomedical data investigation application serving the daily life sciences group, and Twist Bioscience Corporation (NASDAQ: TWST), a business enabling shoppers to be successful via its supplying of higher-top quality artificial DNA working with its silicon platform, currently announced a collaboration aimed at accelerating analysis and lowering the time to design, validate, and commercialize new, higher-excellent, upcoming-technology sequencing (NGS)-primarily based diagnostic checks. As aspect of the collaboration, Twist prospects are equipped to use the built-in DNAnexus system with Twist’s NGS Methylation Detection Process and Exclusive Molecular Identifier (UMI) Adapter Program to simplify knowledge evaluation immediately after sequencing.
The Twist NGS Methylation Detection Method presents strong sample preparation and target enrichment solutions for determining methylated regions in the human genome. Unusual conditions, most cancers, and other problems can be discovered by exceptional methylation designs in samples. The NGS Methylation Detection Method uses remarkably delicate hybridization seize-based mostly know-how that can be integrated into diagnostic checks. This workflow can also be made use of to much better characterize and realize the genetic mechanisms joined to precise disorders together with cancer, neurodegeneration, and unusual illnesses. The Twist UMI Adapter Program detects lower-frequency variants in reduced-enter sample sources such as cell-free of charge DNA (cfDNA) and can be made use of to help cancer investigate. The DNAnexus system enables consumers to quickly examine and examine advanced datasets in a solitary, scalable, cloud-dependent environment.
“This collaboration with DNAnexus is an additional instance of our ongoing motivation to delivering our consumers with the equipment they need for entire, custom made, stop-to-conclusion workflows,” reported Emily M. Leproust, PhD, CEO and co-founder of Twist Bioscience. “Our clients can now accessibility industry-leading computational infrastructure platforms to help their bioinformatics needs and minimize their data examination timeline after executing a sequencing run with our NGS Methylation Detection and UMI Adapter Techniques.”
Today, DNAnexus has far more than 12,000 customers throughout 48 countries and is effective with the major and most modern pharmaceutical providers, diagnostic laboratories, and academic health care facilities around the world, alongside with the Uk Biobank and the Food and drug administration. The platform presents a complete cloud surroundings that supports the overall diagnostic progress and manufacturing cycle from R&D as a result of to deployment of the validated test. The environment was made to meet up with the most arduous benchmarks for top quality, protection, privacy, and security.
“Twist’s proprietary synthetic DNA applications keep on to be utilised to advance research and precision medication and to modify the way diagnostics are produced,” reported John Ellithorpe, PhD, President of DNAnexus. “With the built-in DNAnexus system, Twist buyers can now cut down the elaborate info examination bottleneck, which we imagine will supply sizeable time financial savings and value advantages.”
About Twist Bioscience Corporation
Twist Bioscience is a top and swiftly escalating synthetic biology and genomics company that has designed a disruptive DNA synthesis system to industrialize the engineering of biology. The main of the platform is a proprietary technologies that pioneers a new technique of producing artificial DNA by “writing” DNA on a silicon chip. Twist is leveraging its distinctive technological innovation to manufacture a wide assortment of synthetic DNA-based mostly items, such as synthetic genes, applications for next-generation sequencing (NGS) planning, and antibody libraries for drug discovery and advancement. Twist is also pursuing for a longer period-phrase alternatives in electronic information storage in DNA and biologics drug discovery. Twist would make goods for use across many industries like health care, industrial substances, agriculture, and tutorial investigation.
Adhere to us on Twitter | Facebook | LinkedIn | YouTube
To increase human health, scientists and clinicians want to access elaborate and sensitive biomedical knowledge and impressive technologies that can enable novel insights. Nevertheless, these info are normally incompatible or difficult to process. DNAnexus is the foremost bioinformatics firm that facilitates safe access and utilization of biomedical information although supporting collaboration across inside and exterior groups. From providing an stop-to-conclusion built-in diagnostic R&D and output bioinformatics platform that permits nationwide biobank biomedical initiatives to offering pharmaceutical businesses with a multi-omics knowledge science platform for new goal drug discovery, DNAnexus empowers the healthcare and life sciences field to transform how they leverage biomedical knowledge to speed up scientific discoveries and provide much better client care. For extra details on DNAnexus, make sure you check out www.dnanexus.com or adhere to the organization @DNAnexus.
Twist Legal Discover Regarding Forward-Hunting Statements
This press launch includes forward-searching statements. All statements other than statements of historical specifics contained herein, together with but not limited to the capacity of the collaboration to simplify knowledge examination and speed up analysis and the advancement and implementation of new diagnostic checks, are ahead-hunting statements reflecting the latest beliefs and expectations of management created pursuant to the protected harbor provisions of the Personal Securities Litigation Reform Act of 1995. Forward-on the lookout statements require known and unknown dangers, uncertainties, and other vital elements that may well lead to Twist Bioscience’s genuine effects, effectiveness, or achievements to be materially distinct from any upcoming results, functionality, or achievements expressed or implied by the forward-looking statements. For a description of the hazards and uncertainties that could cause precise effects to differ from individuals expressed in these ahead-looking statements, as nicely as pitfalls relating to Twist Bioscience’s business in typical, see Twist Bioscience’s danger elements established forth in Twist Bioscience’s Quarterly Report on Type 10-Q submitted with the Securities and Trade Commission on May perhaps 6, 2022 and subsequent filings with the SEC. Any forward-on the lookout statements contained in this press release converse only as of the day hereof, and Twist Bioscience particularly disclaims any obligation to update any forward-wanting assertion, irrespective of whether as a end result of new information and facts, potential activities or otherwise.